Gina's story

Gina's story

Gina Savage leaning up against a treeLike most young people, Gina Savage didn’t expect to be at risk of a life-threatening cancer. At just 20 years of age, life was good - with the exception of a very small but annoying lump on her scalp that she noticed when brushing her hair. Little did Gina realise that life as she knew it was about to change forever; she was soon to be diagnosed with melanoma.

After two years of aggressive treatment, Gina and her family were confident that her cancer was gone for good. However, this was just
the beginning of an extremely difficult journey with metastatic melanoma. The once external melanoma had managed to find its way to the lymph nodes in Gina’s head and neck.

In the hope of stopping the cancer in its tracks, Gina underwent four surgeries, four weeks of radiotherapy and endured three difficult
immunotherapy drugs.

Tragically, 12 months ago, a routine scan revealed the cancer had made its way to her lungs. The most effective treatment available for metastatic melanoma, was not working for Gina.

“I don’t know what the next few months will mean for me in terms of disease progression or further treatment, but what I do know is—I will do my best to play my part in preventing others having to endure what I have, by raising awareness for research dedicated to treating and preventing melanoma.”

Gina Savage, who was diagnosed with Metastatic Melanoma.

You are playing your part too by supporting vital melanoma research, directly benefiting patients at Mater, across Australia and around the world. You are giving hope to young people like Gina.

Mater Research is currently running nine immunotherapy clinical trials for a range of cancers. Our hope is that we can create better, more effective options for people based on how their body responds to particular treatments.


Smiling for Smiddy

By choosing to support Smiling for Smiddy you'll be helping fund vital cancer research at Mater—research that is having a national and international impact. Your gift will go towards supporting the dedicated teams of researchers at Mater Research, who are working on potentially life-saving research into the causes and treatment of melanoma, prostate, breast and ovarian cancers.